Nycomed, a pharmaceutical company based in Roskilde near Copenhagen, has expanded its offices in Denmark. A number of group functions and 120 staff have moved into new premises in Taastrup in the greater Copenhagen area. In just five years, Nycomed has increased its staff from 2,400 to more than 3,500, of whom 750 work in Denmark.
Bent Kjærsgaard, managing director of Nycomed Denmark says: "Initially around 120 people have moved from Roskilde to Taastrup, but in the next couple of years the number of staff here is expected to more than double." The majority of Nycomed's group management will be located in Taastrup including group operation which manages all the company's factories throughout Europe.
Over the last few years, Nycomed has implemented a European strategy, establishing branches in the UK, Germany, France, Italy and Spain. According to Bent Kjærsgaard, Nycomed plans to set up more branches in the coming years, in countries including Hungary, the Czech Republic and Romania.
Nycomed employs 3,300 people in Europe and Russia-CIS. The company is owned by capital funds with Nordic Capital as the main shareholder. In 2005, Nycomed generated revenues of DKK 5.6 bn (USD 952 m) and pre-tax profits of DKK 1.2 bn (USD 204 m). The news was reported by national daily newspaper Berlingske Tidende.
Link > Nycomed